Past Events

In this webinar, Le Cong will explore how artificial intelligence (AI) and machine learning (ML) are transforming preclinical development of gene and cell therapies and will also address how AI can shorten development timelines and reduce attrition before clinical translation.

Do you know the key components of a preclinical package needed to move your small molecule project towards clinical trials?

Join our upcoming 1-hour live online webinar.

In this webinar, Pietro Tansini from Rivia will share insights on how AI and big data are transforming clinical development, with a focus on real-time, predictive trial intelligence.

In this joint workshop on Gene and Cell Therapy (GCT), translational scientists aiming to bring their work into clinical practice are invited to discuss the current state and future directions of one of the most dynamic fields shaping the future of medicine.

In this webinar, Stefano Benvenuti will explore how non-profit models — behind Waskyra, the first FDA-approved gene therapy from a non-profit organization — are redefining access for ultra-rare diseases.

In this webinar, Dr. Peggy Sotiropoulou will examine how innovation moves across academia, startups, biotech and pharma, and how spin-offs translate research into products.

In this SPARK-BIH National Gene and Cell Therapies Webinar, Dr. Stefan Frank will present an in-depth overview of bemdaneprocel, one of the first PSC-derived therapies to reach pivotal clinical trials.

Join Dr. Bettina Otto for a 30-minute lunchtime webinar spotlighting current national funding opportunities in Germany for innovative life science research and translational development.

In this SPARK-BIH National Gene and Cell Therapies Webinar, Dr. Günter Harms will cover practical market access approaches such as real-world evidence, HTA reforms, and novel payment models to ensure that breakthrough therapies can reach patients sustainably.

This online SPARK Europe Webinar by Kristian Lund will reveal why the Clinical Evaluation Plan (CEP) and Clinical Evaluation Report (CER) are not just paperwork — they are the foundation of your MDR/IVDR market approval.